CClinicalTrials.gg
Not yet recruitingNCT07761520HMAUpdated Aug 12, 2026

Prevention of Ischemia in Aneurysmal Subarachnoid Hemorrhage Through Remote Ischemic Preconditioning

An interventional study of Remote Ischemic Preconditioning and Sham Ischemic Preconditioning in Aneurysmal Subarachnoid Hemorrhage, sponsored by Centre Hospitalier Universitaire de Nice. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Aneurysmal subarachnoid hemorrhage (SAH) is a severe form of stroke caused by bleeding around the brain. Despite early treatment of the initial hemorrhage, many patients develop delayed cerebral ischemia several days later, which is a major cause of neurological disability, cognitive impairment, and mortality. Current preventive and therapeutic strategies are only partially effective, highlighting the need for new treatment approaches.

This study investigates a simple, non-invasive technique called remote ischemic preconditioning (RIPC). RIPC consists of brief, repeated cycles of limb ischemia and reperfusion induced by a blood pressure cuff. RIPC is thought to activate endogenous protective mechanisms that may improve the brain's tolerance to ischemia. Although beneficial effects have been reported in experimental models and cardiovascular diseases, its clinical efficacy in aneurysmal SAH remains uncertain.

In this randomized, controlled, single-blinded, multicenter study, adult patients admitted with aneyrysmal SAH will be randomly assigned to receive RIPC or a sham procedure. The RIPC group will undergo cycles of brief lower-limb ischemia using a pressure cuff, while the sham group will receive an identical procedure without inducing ischemia. Patients and neurologists assessing outcomes will remain blinded to group allocation.

The intervention will be performed every two days from day 2 to day 10 after hemorrhage. Neurological outcome will be assessed at 3 months using the modified Rankin Scale. Secondary outcomes include mortality at 3 months, long-term neurological and cognitive function outcomes at 12 months, and the incidence of adverse events related to the procedure.

If effective, RIPC could become a simple, low-cost, widely accessible method to reduce disability after SAH. The results may help improve future treatment strategies for this severe condition.

02

Conditions studied

  • Aneurysmal Subarachnoid Hemorrhage

Keywords

  • Aneurysmal Subarachnoid Hemorrhage (aSAH)
  • Remote Ischemic Preconditioning (RIPC)
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age over 18 years
  • Hospitalization for aneurysmal subarachnoid hemorrhage confirmed by CT scan and/or lumbar puncture
  • Confirmation of intracranial aneurysm by CT angiography and/or cerebral angiography
  • Written informed consent obtained from the patient or legal representative
  • Affiliation to a social security system

Exclusion criteria

Exclusion Criteria:

  • Skin, orthopedic, or vascular conditions of the limbs contraindicating ischemic preconditioning (e.g., ulcers, fractures, deep vein thrombosis)
  • Pregnancy
  • Withdrawal of informed consent
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Ischemic Preconditioning (RIPC)

    Procedure: Remote Ischemic Preconditioning

  • Placebo comparator
    Sham Procedure

    Procedure: Sham Ischemic Preconditioning

Interventions

  • ProcedureRemote Ischemic Preconditioning

    Three cycles of lower-limb ischemia and reperfusion using a blood pressure cuff inflated to 20 mmHg above systolic blood pressure for 5 minutes followed by 5 minutes of reperfusion. The procedure is performed every two days from day 2 to day 10 after aneurysmal subarachnoid hemorrhage.

  • ProcedureSham Ischemic Preconditioning

    Identical procedure to the experimental arm, except the cuff is inflated to only 30 mmHg, insufficient to induce ischemia, giving the sensation of pressure without therapeutic effect. Performed every two days from day 2 to day 10 post-hemorrhage.

05

What researchers measure

Primary outcomes

  1. Neurological Functional Outcome at 3 Months (mRS)

    Assessment of neurological disability and dependency using the modified Rankin Scale (mRS) performed by a blinded neurologist. The mRS is a 6-point scale (0 to 5), with 5 being a severe disability.

    Time frame: 3 months (+/- 15 days) post-aneurysmal subarachnoid hemorrhage

Secondary outcomes

  1. Evaluation of mortality at 3 Months

    Comparison of all-cause mortality between the RIPC group and the sham group

    Time frame: From day 0 to 3 months post-hemorrhage

  2. Long-term Neurological Outcome at 12 Months (mRS)

    Assessment of long-term neurological disability and dependency using the modified Rankin Scale (mRS) performed by a blinded neurologist. The mRS is a 6-point scale (0 to 5), with 5 being a severe disability.

    Time frame: 12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhage

  3. Evaluation of Cognitive Function at 12 months (MMSE)

    Evaluation of cognitive performance assessed using the Mini-Mental State Examination (MMSE). The MMSE score ranks from 0 to 30, with 30 being a normal congnitive performance and 0 serious cognitive impairments.

    Time frame: 12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhage

  4. Evaluation of Cognitive Function at 12 months (MoCA)

    Evaluation of cognitive performance assessed using the Montreal Cognitive Assessment (MoCA). The MoCA is scored out of 30 points, with high scores suggesting mild or no cognitive impairments, and low scores severe cognitive impairments.

    Time frame: 12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhage

  5. Safety Outcomes

    Incidence, nature, and severity of adverse events and serious adverse events occurring during the study period.

    Time frame: From day 0 until 12 months post-aneurysmal subarachnoid hemorrhage.

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07761520
Lead sponsor
Centre Hospitalier Universitaire de Nice
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Aug 12, 2026

Study contacts

Jacques Sedat, MD
Contact
sedat.j@chu-nice.fr
+33 4 92 03 38 07
Eve Ledoux
Contact
ledoux.e@chu-nice.fr
+33 4 92 03 27 29

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion